1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. News
  7. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Swedish Orphan Biovitrum Gets Positive Opinion From European Medicines Agency For COVID-19 Pneumonia Treatment

12/16/2021 | 10:02am EDT


© MT Newswires 2021
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
05/10Swedish Orphan Biovitrum AB Elects Bo Jesper Hansen as New Board Member
CI
04/28Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March ..
CI
04/28TRANSCRIPT : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Swedish Drugmaker Sobi Confirms FY22 Revenue Outlook After Q1 Growth
MT
04/28Drugmaker Sobi books profit fall on restructuring, Russia
RE
04/28Sobi publishes Q1 2022 report
AQ
04/28Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Year 2022
CI
04/20INVITATION : Sobi's Q1 2022 report
AQ
04/06Swedish Orphan Biovitrum AB - Annual and Sustainability Report 2021
AQ
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Financials
Sales 2022 17 553 M 1 784 M 1 784 M
Net income 2022 2 377 M 242 M 242 M
Net Debt 2022 6 950 M 706 M 706 M
P/E ratio 2022 26,7x
Yield 2022 -
Capitalization 62 101 M 6 312 M 6 312 M
EV / Sales 2022 3,93x
EV / Sales 2023 3,44x
Nbr of Employees 1 569
Free-Float 58,8%
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | SOBI | SE0000872095 | MarketScreener
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 210,40 SEK
Average target price 245,88 SEK
Spread / Average Target 16,9%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Anne Marie de Jonge Schuermans Head-Technical Operations & Senior Vice President
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Sector and Competitors